| Old Articles: <Older 8001-8010 Newer> |
|---|
 |
The Motley Fool
October 27, 2011
Alexander Crawford |
Medical Devices: Venture Capitalists Lobby to Change FDA Approval Process Do you think these firms stand to benefit from new regulations?   |
The Motley Fool
October 27, 2011
Sean Williams |
Idenix Pharmaceuticals Shares Popped: What You Need to Know Shares of biopharmaceutical company Idenix Pharmaceuticals jumped as much as 26% earlier in the trading session before paring the majority of its gains despite any company-specific news. |
The Motley Fool
October 26, 2011
Tim Beyers |
Thermo Fisher Scientific Shares Plunged: What You Need to Know Shares of Thermo Fisher Scientific fell more than 10% in early trading and closed off almost that much after lowering full-year earnings and revenue guidance. |
The Motley Fool
October 26, 2011
Brian Orelli |
Momenta Stopped. Again. Oh, no - an authorized generic gets launched. |
The Motley Fool
October 26, 2011
Brian Orelli |
Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. |
Chemistry World
October 26, 2011
Maria Burke |
Europe risks being outstripped by R&D rivals EU companies are lagging behind in R&D investment compared with major competitors from the US and some Asian economies, according to the European Commission's 2011 EU Industrial R&D Investment Scoreboard. |
The Motley Fool
October 26, 2011
G. A. Chester |
Glaxo Returns to Growth The U.K.'s No. 1 drug company still looks like a good value. |
The Motley Fool
October 26, 2011
Chris Baines |
Why Getting A Flu Shot Is Critical Vaccines save the lives of millions. By getting a flu shot, you're also aiding future vaccine research conducted by major pharmaceutical companies. |
The Motley Fool
October 26, 2011
Selena Maranjian |
Make Money in Promising Biotech Stocks the Easy Way If you expect the biotech industry to thrive as scientists develop more drugs to treat our aging population, the iShares Nasdaq Biotechnology ETF could be for you. |
The Motley Fool
October 25, 2011
Brian Orelli |
Anemic Growth in All the Right Places Amgen's anemia drugs decline, but that's not its future anyway. |
| <Older 8001-8010 Newer> Return to current articles. |
